Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

All NewsApril 9, 2026

JNJ (NYSE: JNJ) to release Q1 earnings before bell on April 14. Analysts expect $2.67/share & $23.6B revenue. FDA approves TECNIS PureSee lens.

Latest Ratings for JNJ

DateFirmActionFromTo Jan 2022Raymond JamesMaintainsOutperform Jan 2022Morgan StanleyMaintainsEqual-Weight Dec 2021Goldman SachsInitiates Coverage OnNeutral

View More Analyst Ratings for JNJ

View the Latest Analyst Ratings

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent